| P50 | author | Arnold S. Monto | Q59829998 |
| | Joshua G Petrie | Q89457943 |
| | Emily T Martin | Q106490444 |
| P2093 | author name string | Peter B Gilbert | |
| | Lindsay N Carpp | |
| | Youyi Fong | |
| | Michal Juraska | |
| P2860 | cites work | Serologic studies of acute respiratory infections in military personnel | Q27487427 |
| | Comparing biomarkers as principal surrogate endpoints | Q28740935 |
| | Influenza vaccine: the challenge of antigenic drift. | Q30363606 |
| | Influenza neuraminidase as a vaccine antigen. | Q30364823 |
| | Effect of Repeated Vaccination With the Same Vaccine Component Against 2009 Pandemic Influenza A(H1N1) Virus | Q30401497 |
| | Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies | Q30405145 |
| | Influence of prior influenza vaccination on antibody and B-cell responses | Q33361605 |
| | Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. | Q45729513 |
| | Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period | Q45760959 |
| | Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. | Q50637887 |
| | Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season | Q58709341 |
| | Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness | Q70443341 |
| | Evaluation of monovalent influenza vaccines. II. Observations during an influenza a-prime epidemic | Q75876534 |
| | Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years | Q79635571 |
| | Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection | Q85094818 |
| | Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America | Q89453187 |
| | Inference on treatment effect modification by biomarker response in a three-phase sampling design | Q90779133 |
| | Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model | Q33538308 |
| | Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates | Q33554684 |
| | A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes | Q33712709 |
| | Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus | Q34028740 |
| | Principal stratification in causal inference | Q34065063 |
| | Global analyses of human immune variation reveal baseline predictors of postvaccination responses | Q34070648 |
| | Serologic assays for influenza surveillance, diagnosis and vaccine evaluation | Q34194336 |
| | Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons | Q34393525 |
| | Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. | Q34430200 |
| | Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures | Q34754945 |
| | Influenza vaccines: challenges and solutions | Q35184572 |
| | Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population | Q35191251 |
| | Quantifying influenza vaccine efficacy and antigenic distance. | Q35760689 |
| | Some extensions in continuous models for immunological correlates of protection | Q35878996 |
| | Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine | Q36151974 |
| | Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis | Q36250022 |
| | Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination | Q36306922 |
| | Variable efficacy of repeated annual influenza vaccination | Q36705674 |
| | Augmented designs to assess immune response in vaccine trials | Q36877243 |
| | Influenza vaccine effectiveness in the community and the household | Q36956943 |
| | Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model | Q37123064 |
| | Sequential mutations in hemagglutinins of influenza B virus isolates: definition of antigenic domains | Q37343329 |
| | Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults | Q38124061 |
| | Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial | Q38852557 |
| | Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital | Q39525235 |
| | Determinants of immunity to influenza infection in man | Q39784922 |
| | Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season | Q39837983 |
| | Antigenic drift in the evolution of H1N1 influenza A viruses resulting from deletion of a single amino acid in the haemagglutinin gene | Q40048713 |
| | Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time | Q40931032 |
| | Surrogate endpoints in clinical trials: definition and operational criteria | Q41310696 |
| | Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults | Q41326434 |
| | Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection | Q41347626 |
| | An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera | Q42186897 |
| | Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons | Q42239081 |
| | Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine | Q42242172 |
| | The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses | Q42790878 |
| | Evaluating candidate principal surrogate endpoints | Q43070037 |
| | Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children | Q43963300 |
| | Comparative efficacy of inactivated and live attenuated influenza vaccines | Q44677378 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine efficacy | Q7907952 |
| | influenza vaccine | Q383260 |
| | attenuated vaccine | Q1810913 |
| | infectious disease | Q18123741 |
| P304 | page(s) | 453 | |
| P577 | publication date | 2019-05-22 | |
| P1433 | published in | BMC Infectious Diseases | Q15759919 |
| P1476 | title | HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy | |
| P478 | volume | 19 | |